2022 Development Timelines
1AD - 2022 Goals
Significantprogress anticipated on both existing core programs and further pipelineexpansion
AD-214 – First in class anti-fibrotic
• Inhaledformulation development: nebulisation feasibility, efficacy in animal model ofIPF (Q1); lung distribution imaging in healthy and disease model animals (Q1);dose finding and clinical formulation (Q2)
• Intravenousformulation development (Q3)
• GLP toxicologywith inhaled formulation (commences 2H22)
• Continuing partneringdiscussions (Q1); selection of next indication
GE Healthcare – GZMB PET imaging
• Pre-clinicalproof of concept – milestone payment (mid-22)
Carina Biotech – i-body enabled CAR-T cells
• 1stexperimental results on Target #1
• Commencei-body discovery on Target #2
Internal pipeline and platform development
• Initialfunctional data on i-body binders against internal Target #2 (2H22)
• i-body2.0: newintellectual property filed (end’22)
• 7 programs inpipeline (end’22)
• Additionalpatent filings, grants on individual i-body enabled products
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(16.7%) |
Mkt cap ! $2.886M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.3¢ | 0.2¢ | $5.045K | 2.078M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 36 | 38740273 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 13870722 | 16 |
View Market Depth
| Last trade - 13.18pm 13/08/2025 (20 minute delay) ? |
| 1AD (ASX) Chart |